Evidence map›Paper›PMID 28167659›Full record

Trial reportBlood2017

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Ariela Noy, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher R Flowers, Franck Morschhauser, Graham P Collins, Shuo Ma, Morton Coleman, Shachar Peles and 7 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01980628 (A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase), which is not on this map. Cited by 141 papers.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed
20.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01980628 phase2completednot on this map

A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

TypeinterventionalSponsorPharmacyclics LLC.Ran2013 to 2017Enrolled63ConditionsMarginal Zone Lymphoma, B-cell LymphomaArmsibrutinib
3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 288 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Lenalidomide plus rituximab (RBritish journal of haematology · 2019
    Trial
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Ivermectin Treatment forCase reports in hematology · 2026
    Article
  17. Article
  18. Article
  19. Review
  20. Article

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 3 countries.

Ariela NoyLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Sven de VosDavid Geffen School of Medicine at UCLA, Los Angeles, CA.
Catherine ThieblemontHemato-oncology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris Diderot University, Sorbonne Paris-Cité, Paris, France.
Peter MartinWeill Department of Medicine, Weill Cornell Medical College, New York, NY.
Christopher R FlowersWinship Cancer Institute of Emory University, Atlanta, GA.
Franck MorschhauserHematologie, Centre Hospitalier Universitaire, Université de Lille, Lille, France.
Graham P CollinsDepartment of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Shuo MaRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Morton ColemanClinical Research Alliance, Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY.
Shachar PelesFlorida Cancer Specialists, Atlantis, FL.
Stephen SmithDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Jacqueline C BarrientosDivision of Hematology and Medical Oncology, Department of Medicine, Hofstra Northwell School of Medicine, Hempstead, NY.
Alina SmithPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and.
Brian MunnekePharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and.
Isaiah DimeryPharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and.
Darrin M BeauprePharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and.
Robert ChenCity of Hope National Medical Center, Duarte, CA.
Cornell University · USAbbVie (United States) · USPharmacyclics (United States) · USCentre Hospitalier Universitaire de Lille · FRCity Of Hope National Medical Center · USEmory University · USFlorida Cancer Specialists & Research Institute · USHofstra University · USHôpital Saint-Louis · FRNorthwestern University · USOxford University Hospitals NHS Trust · GBUniversity of California, Los Angeles · USUniversity of Washington Medical Center · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
NCI NIH HHS P30 CA060553
6 · The paper itself

Abstract

Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no standard treatment exists. MZL is frequently linked to chronic infection, which may induce B-cell receptor (BCR) signaling, resulting in aberrant B-cell survival and proliferation. We conducted a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of ibrutinib in previously treated MZL. Patients with histologically confirmed MZL of all subtypes who received ≥1 prior therapy with an anti-CD20 antibody-containing regimen were treated with 560 mg ibrutinib orally once daily until progression or unacceptable toxicity. The primary end point was independent review committee-assessed overall response rate (ORR) by 2007 International Working Group criteria. Among 63 enrolled patients, median age was 66 years (range, 30-92). Median number of prior systemic therapies was 2 (range, 1-9), and 63% received ≥1 prior chemoimmunotherapy. In 60 evaluable patients, ORR was 48% (95% confidence interval [CI], 35-62). With median follow-up of 19.4 months, median duration of response was not reached (95% CI, 16.7 to not estimable), and median progression-free survival was 14.2 months (95% CI, 8.3 to not estimable). Grade ≥3 adverse events (AEs; >5%) included anemia, pneumonia, and fatigue. Serious AEs of any grade occurred in 44%, with grade 3-4 pneumonia being the most common (8%). Rates of discontinuation and dose reductions due to AEs were 17% and 10%, respectively. Single-agent ibrutinib induced durable responses with a favorable benefit-risk profile in patients with previously treated MZL, confirming the role of BCR signaling in this malignancy. As the only approved therapy, ibrutinib provides a treatment option without chemotherapy for MZL. This study is registered at www.clinicaltrials.gov as #NCT01980628.

Indexed as

AdenineAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAnemiaAntineoplastic AgentsB-LymphocytesDisease-Free SurvivalDrug Administration ScheduleFatigueFemaleHumansImmunotherapyLymphoma, B-Cell, Marginal ZoneMaleAdenineAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsibrutinibPiperidinesProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyrimidines

Identifiers

PMID28167659
PMCPMC5399483
OpenAlexW2587684973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.